Elekta AB (EKTA-B) Fair Value & Analysis
Healthcare · SE · Market cap 19.6B SEK
Fair value as of: Jul 11, 2026
From 14 valuation models · updated 10 days ago
Fair value updated Jul 11, 2026, revised from kr 52.86 to kr 8.81 (−83.3%) since Jun 24, 2026. Share price −4.0% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 41.49 – kr 62.55 · fair‑value band kr 8.81 – kr 13.84 · the kr 46.60 price screens above the kr 8.81 fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Elekta AB (EKTA-B) currently trades at kr 46.60, while our model-based Fair Value estimate is kr 8.81, implying the stock looks roughly 81.1% overvalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Elekta AB generated revenue of 16.7B SEK at a net margin of -3.1%. Revenue declined 7.6% year over year. It earns a return on equity of -6.5%. Net debt stands at 4.1B SEK. Fundamentals as of Jul 11, 2026
Our scenario range runs from kr 8.81 (bear case) to kr 13.84 (bull case); at kr 46.60, the current price sits above that range. The share trades about 29% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -81%, EKTA-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Leksell GammaPlan, a treatment planning and management software, as well as Elekta ONE, an oncology software suite. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Elekta AB reported revenue of kr 16.7B in FY2026 versus kr 14.5B in FY2022, a compound +3.5%/yr. Reported net income was −kr 520M in FY2026.
Is EKTA-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $86.97 | $69.36 | -20% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| Koninklijke Philips N.V PHG | $26.61 | $12.54 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Elekta AB (EKTA-B) undervalued?
What is the fair value of EKTA-B?
What is the quality score of EKTA-B?
What is the revenue of Elekta AB (EKTA-B)?
What is the net profit margin of EKTA-B?
Does Elekta AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Elekta AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.